



Published in final edited form as:

*Immunol Lett.* 2016 May ; 173: 61–68. doi:10.1016/j.imlet.2016.03.005.

## Acquisition of negative complement regulators by the saprophyte *Leptospira biflexa* expressing LigA or LigB confers enhanced survival in human serum

Mónica M. Castiblanco-Valencia<sup>a</sup>, Tatiana R. Fraga<sup>a</sup>, Leandro C.D. Breda<sup>a</sup>, Sílvio A. Vasconcellos<sup>b</sup>, Cláudio P. Figueira<sup>c</sup>, Mathieu Picardeau<sup>d</sup>, Elsie Wunder<sup>e</sup>, Albert I. Ko<sup>c,e</sup>, Angela S. Barbosa<sup>f</sup>, and Lourdes Isaac<sup>a,\*</sup>

<sup>a</sup>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

<sup>b</sup>Faculty of Veterinary Medicine, University of São Paulo, São Paulo, Brazil

<sup>c</sup>Oswaldo Cruz Foundation, Salvador, Bahia, Brazil

<sup>d</sup>Institut Pasteur, Biology of Spirochetes Unit, Paris, France

<sup>e</sup>Department of Epidemiology of Microbial Diseases, Yale University, EUA, CT, USA

<sup>f</sup>Laboratory of Bacteriology, Butantan Institute, São Paulo, Brazil

### Abstract

Leptospiral immunoglobulin-like (Lig) proteins are surface exposed molecules present in pathogenic but not in saprophytic *Leptospira* species. We have previously shown that Lig proteins interact with the soluble complement regulators Factor H (FH), FH like-1 (FHL-1), FH related-1 (FHR-1) and C4b Binding Protein (C4BP). In this study, we used the saprophyte *L. biflexa* serovar Patoc as a surrogate host to address the specific role of LigA and LigB proteins in leptospiral complement evasion. *L. biflexa* expressing LigA or LigB was able to acquire FH and C4BP. Bound complement regulators retained their cofactor activities of FI in the proteolytic cleavage of C3b and C4b. Moreover, heterologous expression of *ligA* and *ligB* genes in the saprophyte *L. biflexa* enhanced bacterial survival in human serum. Complement deposition on *lig*-transformed *L. biflexa* was assessed by flow cytometry analysis. With regard to MAC deposition, *L. biflexa* expressing LigA or LigB presented an intermediate profile: MAC deposition levels were greater than those found in the pathogenic *L. interrogans*, but lower than those observed for *L. biflexa* wildtype. In conclusion, Lig proteins contribute to *in vitro* control of complement activation on the leptospiral surface, promoting an increased bacterial survival in human serum.

### Keywords

*Leptospira*; Complement; Immune evasion; Lig proteins; Factor H; C4BP

\*Corresponding author at: Av. Prof. Lineu Prestes 1730, 05508-900 São Paulo, SP, Brazil., louisaac@icb.usp.br (L. Isaac).

## 1. Introduction

Leptospirosis is an important human and veterinary health problem and one of the most widespread zoonosis in the world. The Caribbean, Central and South America, as well as Southeast Asia and Oceania, are highly endemic for the disease [1]. In urban environments, rodent-borne transmission is the predominant epidemiological pattern of the disease. Flood-prone regions lacking proper sanitation facilities deeply contribute to epidemics of leptospirosis in tropical areas [2].

The genus *Leptospira* includes pathogenic and saprophytic species, which are classified into more than 300 serovars based on the structural heterogeneity of the lipopolysaccharide (LPS) carbohydrate moiety [3]. Pathogenic *Leptospira* have evolved different immune evasion strategies that allow them to survive and spread in the host (reviewed in [4]). In this context, it has been demonstrated that pathogenic *Leptospira* strains are more resistant to the action of the human complement system than the saprophytic ones, such as *Leptospira biflexa*. Serum resistance is achieved by the acquisition of negative complement regulators on their surfaces, such as Factor H (FH) and C4b Binding Protein (C4BP), and also by the secretion of proteases that inactivate key complement proteins from the three pathways [5–7].

FH, a 150-kDa plasma protein, is the major negative regulator of the alternative pathway (AP) of complement. It inhibits AP by accelerating the decay of the C3 convertase, C3bBb, and by acting as a cofactor of Factor I (FI) in C3b cleavage [8–10]. *Leptospira*-bound FH remains functionally active and confers a protective role, being crucial for bacterial survival in human [6,11]. Pathogenic *Leptospira* also have the ability to bind human C4BP, a 570-kDa plasma glyco-protein that is a key fluid phase inhibitor of the classical and lectin pathways of complement [12,13]. C4BP interferes with the assembly and decay of the C3-convertase, C4bC2a, and acts as a cofactor of FI in the proteolytic inactivation of C4b. *Leptospira*-bound C4BP retains cofactor activity, indicating that the acquisition of this complement regulator may contribute to leptospiral serum resistance [5].

In a recent work we demonstrated that Leptospiral Immunoglobulin-like proteins A and B (LigA and LigB) interact with FH, C4BP and also with two other members of the FH family: FH like-1 (FHL-1) and FH related-1 (FHR-1). Both FH and C4BP bound to the Lig proteins remain functional, acting as cofactors for FI in the proteolytic cleavage of C3b and C4b, respectively [11]. The *lig* genes are present in pathogenic but not in saprophytic *Leptospira* species, and their expression is associated with host infection, being controlled by osmolarity, a key environmental factor which enhances binding of *Leptospira* to host cells [14,15]. *In vitro* studies have shown that Lig proteins interact with extra-cellular matrix proteins such as fibronectin, laminin, collagen, fibrinogen, elastin and tropoelastin [16–23]. Antibody responses to Lig proteins are induced in human leptospirosis patients and in infected animals [24–26]. A fragment of the LigA protein has been shown to be a promising vaccine candidate, conferring high-levels of protection in hamster models of leptospirosis [27,28]. Together these findings indicate that Lig proteins are multifunctional proteins that may contribute to *Leptospira* adhesion and immune evasion during infection. However, disruption of the *ligB* gene did not affect *Leptospira* virulence in hamster model [29].

Expression of other leptospiral surface proteins involved in host colonization may compensate the loss of LigB expression, a phenomenon known as functional redundancy [29].

In this study, we used the saprophyte *L. biflexa* serovar Patoc as a surrogate host to address the specific role of Lig proteins in leptospiral immune evasion. In a previous work, Figueira and colleagues [30] reported that heterologous expression of LigA and LigB in *L. biflexa* was able to confer enhanced bacterial adhesion to eukaryotic cells and fibronectin *in vitro* [30], which prompted us to use this system to analyze the isolated role of Ligs in the leptospiral complement evasion.

## 2. Material and methods

### 2.1. Complement proteins, antibodies and sera

The complement proteins purified from human plasma (FH, C4BP, C3b and C4b) and the goat anti-human C3 and anti-human C4 polyclonal antibodies were purchased from Complement Technology. Goat anti-human FH polyclonal antibody was obtained from Quidel. Rabbit anti-human C4BP and anti-human C5b-9 (MAC) polyclonal antibodies were purchased from Calbiochem. Donkey anti-goat IgG FITC conjugated and donkey anti-rabbit IgG FITC or PE conjugated were obtained from Abcam. Normal human serum (NHS) was obtained from healthy volunteers, after informed consent (869/CEP). Inactivated NHS (HI-NHS) was prepared by heating the serum at 56 °C for 60 min.

### 2.2. Bacteria strains

The following strains were used in this study: non-pathogenic *L. biflexa* serovar Patoc strain Patoc I (Patoc wt), pathogenic *L. interrogans* serovar Kennewicki strain Fromm and *L. biflexa* serovar Patoc strain Patoc I expressing LigA (Patoc *ligA*) or LigB (Patoc *ligB*) [30]. *Leptospira* strains were cultivated at 29 °C for seven days, under aerobic conditions in liquid EMJH medium (Difco) supplemented with *Leptospira* EMJH Enrichment (BD). Patoc *ligA* and Patoc *ligB* were grown in culture medium containing spectinomycin at the final concentration of 50 µg/ml [30].

### 2.3. Interaction of *Leptospira* strains with FH and C4BP

Freshly harvested leptospire (1 × 10<sup>8</sup> bacteria) were washed with PBS pH 7.4 and incubated with 10% NHS, as a source of FH and C4BP, for 60 min at 37 °C. Leptospire were then washed five times with PBS, harvested and subjected to 12% SDS-PAGE under reducing conditions. The proteins were transferred to nitrocellulose membranes, and nonspecific binding sites were blocked using 10% (w/v) dried milk in PBS-Tween (0.05%) (pH 7.4) overnight at 4°C. The membranes were incubated with goat anti-human FH (1:10000) or rabbit anti-human C4BP (1:5000) polyclonal antibodies, followed by peroxidase-conjugated secondary antibodies, for 60 min. Positive signals were detected by enhanced chemiluminescence (SuperSignal West Pico, Pierce). Densitometry analysis of the bands was performed using the program ImageJ.

## 2.4. Serum susceptibility assay

Freshly harvested leptospires were washed once with PBS pH 7.4 and counted by dark-field microscopy using a Petroff-Hausser chamber. Bacteria ( $5 \times 10^8$ ) were incubated with 20, 40 and 60% NHS, or 60% HI-NHS for 60 or 120 min at 37 °C. After incubation, leptospiral survival in each treatment was assessed by counting viable bacteria. Leptospires susceptible to complement attack fragment in fine particles, losing their typical morphology. Three independent experiments were performed. The treatment with HI-NHS was considered as 100% of survival.

## 2.5. Cofactor activity assay

Cofactor activity of FH or C4BP bound to leptospires was assessed by measuring FI-mediated cleavage of C3b (FH as a cofactor) or C4b (C4BP as a cofactor). Leptospires ( $2 \times 10^8$  bacteria) were incubated with 5% NHS or 2  $\mu$ g of FH or C4BP for 60 min at 37 °C. After washing with PBS, 250 ng of FI and 500 ng of C3b or C4b were added. The reactions were incubated for 60, 120 and 240 min at 37 °C, and then subjected to Western blotting. The cleavage fragments of C3b and C4b were detected with goat anti-human C3 or anti-human C4 polyclonal antibodies (1:5000), followed by incubation with secondary peroxidase-conjugated antibodies (1:10000), by enhanced chemiluminescence (SuperSignal West Pico, Pierce).

## 2.6. Analysis of complement deposition by flow cytometry

Leptospires ( $2 \times 10^8$  bacteria) were incubated with 20% NHS or PBS (negative control) in a final volume of 100  $\mu$ l for 60 min. After five washes with PBS, bacteria were incubated with anti-human C3, anti-human C4 or anti-human MAC polyclonal antibodies (1:100; in PBS containing 1% BSA) for 30 min. Leptospires were then washed with PBS, and mouse anti-goat IgG FITC-conjugated or anti-rabbit IgG PE-conjugated (1:200; in PBS containing 1% BSA) were added and incubated for 30 min. After three washes, bacteria were suspended with PBS in a final volume of 300  $\mu$ l. As negative controls, untreated leptospiral suspensions were incubated only with primary and secondary antibodies. Leptospires were detected using log-forward and log-side scatter dot-plot. The gate was drawn to exclude debris and larger aggregates of bacteria—10,000 bacteria/events were captured per experiment. Data are expressed as Mean Fluorescence Intensity (MFI)  $\pm$  SE of three independent experiments each performed in triplicate on a Fluorescent Activated Cell Sorter (FACS) Canto II (Benton Dickson). Data were analyzed by FlowJo Software (version 8.7).

## 2.7. Statistical analysis

Data were analyzed using ANOVA-Tukey's Multiple Comparison Test and *p* values are indicated in each figure legend.

## 3. Results

### 3.1. Patoc *ligA* and Patoc *ligB* interact with FH and C4BP

LigA and LigB expression by the *lig*-transformed Patoc strains was previously assessed by Western blot analysis [30]. Both strains showed levels of protein comparable to the

production by a low *in vitro*-passaged *L. interrogans* virulent strain. In addition, Patoc wt, *ligA*, and *ligB* strains were shown to have similar cell growth kinetics in EMJH liquid medium and immunofluorescence studies indicated that LigA and LigB are surface-exposed when expressed in transformed Patoc strains [30].

In a previous work we have shown that Lig proteins interact with the soluble complement regulators FH and C4BP [11]. To assess if *lig*-transformed *L. biflexa* strains are able to acquire these negative complement regulators, bacteria were incubated with 20% NHS, and then submitted to Western blot analysis with specific antibodies against the complement proteins. Both Patoc *ligA* and Patoc *ligB* acquired FH and C4BP from human serum (Fig. 1). The wild type *L. biflexa* bound negligible amounts of both complement regulators to its surface, but acquisition of FH and C4BP was markedly increased by the expression of Lig proteins in *L. biflexa*, suggesting a role for these molecules in *Leptospira* complement evasion.

### 3.2. Heterologous expression of *ligA* and *ligB* genes in the saprophyte *L. biflexa* enhances bacterial survival in human serum

To specifically address the role of LigA and LigB in complement evasion, *lig*-transformed *L. biflexa* strains were subjected to serum susceptibility assays. Leptospire were incubated in different NHS concentrations, and viable bacteria were then counted using dark field microscopy. The survival percentage of Patoc *ligA* and Patoc *ligB* was approximately 2-fold higher in 60% NHS than that of Patoc wt (Fig. 2, left). Differences in survival were even more pronounced when bacteria were incubated in NHS for 120 min (Fig. 2, right). In 60% NHS (120 min), about 85% of Patoc wt were eliminated by complement-mediated lysis, while approximately 50% of Patoc *ligA* and Patoc *ligB* remained viable. The survival rates of *lig*-transformed *L. biflexa* strains were intermediate between the ones observed for the saprophyte *L. biflexa* and the pathogenic *L. interrogans* (Fig. 2). This profile indicates that heterologous expression of *ligA* and *ligB* in *L. biflexa* enhances *in vitro* survival of this saprophytic strain in the presence of complement system. However, other molecules expressed by the pathogenic *L. interrogans* strain may also contribute to complement evasion.

### 3.3. FH and C4BP bound to Patoc *ligA* and Patoc *ligB* retain cofactor activity

As *lig*-transformed *L. biflexa* strains acquire negative complement regulators and present an increased survival in human serum compared to *L. biflexa* wt, we decided to assess the functionality of these complement molecules bound to the bacterial surface. Leptospire were incubated with purified FH, C4BP or NHS and, after washing, the serine protease FI and the substrates C3b (FH as a cofactor) or C4b (C4BP as a cofactor) were added. The cleavage fragments of C3b and C4b were detected by Western blotting with specific antibodies. FH and C4BP bound to Patoc *ligA* and to Patoc *ligB* were capable of acting as cofactors of FI in the cleavage of C3b (Fig. 3A) and C4b (Fig. 3B). The degradation of the C3b  $\alpha'$ -chain (~101 kDa) generated fragments of approximately 68, 46, 43, 38, 30 and 28 kDa when NHS was used as a source of FH (Fig. 3A). The cleavage of the C4b generated bands of approximately 64 kDa and 17 kDa (Fig. 3B). C3b and C4b cleavages can be already detected in the first hour of incubation. Interestingly, cofactor activities were more

efficient when serum was used as a source of FH or C4BP. Taken together, our data strongly suggest that Lig proteins may play an important role in leptospiral resistance to complement-mediated killing.

### 3.4. Patoc *ligA* and Patoc *ligB* control MAC deposition

The enhanced survival of *lig*-transformed *L. biflexa* strains in human serum prompted us to further investigate the deposition of other complement proteins on the bacterial surface. Leptospire were incubated with human serum and then specific antibodies against C3, C4 or MAC were added. Complement deposition was analyzed by flow cytometry. A reduced deposition of C3/C3 fragments was observed on Patoc *ligB* compared to Patoc wt, and no significant difference was found between Patoc *ligB* and *L. interrogans* regarding C3 deposition. However, Patoc *ligA* significantly presented greater levels of C3 deposition compared to *L. interrogans* (Fig. 4A). The profile of C4/C4 fragments deposition was more homogeneous among the four strains tested. In this case, a significant statistical difference was only observed between *L. biflexa* Patoc wt and *L. interrogans* Fromm, the latter showing lower levels of C4 deposition (Fig. 4B). With regard to MAC deposition, *lig*-transformed *L. biflexa* strains presented an intermediate profile: MAC deposition levels were greater than those found in *L. interrogans* (Fromm), but clearly lower than those observed for *L. biflexa* (Patoc wt) (Fig. 4C). This intermediate behavior demonstrates that the expression of Lig proteins contribute to the control of complement activation on the leptospiral surface, thus promoting an increased bacterial survival in human serum.

## 4. Discussion

Differences regarding susceptibility to host's serum among *Leptospira* strains were first reported in the mid-1960s [31,32]. A direct correlation between virulence and the capacity to resist complement-mediated killing was already clear at that time. Knowledge of the mechanisms beyond *Leptospira* resistance was expanded over the last years by the demonstration that pathogenic *Leptospira* strains present multiple complement evasion strategies such as the secretion of proteases that inactivate key complement proteins [7] and the acquisition of soluble host complement regulators on their surfaces [5,6,11,33,34]. By binding these fluid-phase regulators virulent strains avoid serum bactericidal activity more efficiently than culture-attenuated or non-pathogenic *Leptospira* strains [5,6].

In a recent report, we have shown that recombinant LigA and LigB bind FH, FHL-1, FHR-1 and C4BP [11], thus potentially enabling control of host's innate immune responses. To further evaluate the relevance of these multifunctional surface proteins in leptospiral complement evasion, we employed the non-pathogenic *L. biflexa* serovar Patoc as a surrogate host expressing LigA or LigB. It has been previously shown that *L. biflexa* serovar Patoc is susceptible to serum bactericidal activity [5,6] and is devoid of all genes that encode well-characterized leptospiral immune evasion proteins described to date, including LenA, LenB, LigA, LigB, and LcpA [11,34–36]. In this work, the capacity of *lig*-transformed *L. biflexa* strains to acquire FH and C4BP from human serum was evaluated. Our data demonstrate that Patoc *ligA* and Patoc *ligB* bind significant amounts of both complement regulators (Fig. 1), what can explain an increased survival of both strains in human serum



compared to Patoc wt (Fig. 2). From our results, we can infer that Lig proteins are important players in conferring leptospiral serum resistance *in vitro*. In addition, other surface proteins, such as LenA, LenB and LcpA [34–36], may also contribute to this process, ensuring a successful survival of these spirochetes inside the host.

Functionality of FH and C4BP bound to Patoc *ligA* and Patoc *ligB* was also assessed. Both complement regulators retained cofactor activity when purified proteins or human serum were used as a complement source (Fig. 3). Cleavages of C3b and C4b were more efficient in the presence of human serum, probably due to a more preserved structural conformation of both complement regulators, which did not undergo a purification process. In Patoc *ligA* and Patoc *ligB*, the degradation profile of C3b using NHS as a source of FH was similar to that observed for the virulent strain *L. interrogans* serovar Pomona [11]. In both cases, FI cleaved C3b  $\alpha'$  chain (110 kDa) generating cleavage products ranging from 28 to 68 kDa.

Next, we evaluated deposition of complement components C3 and C4 fragments and MAC on the surface of *lig*-transformed *L. biflexa* strains. According to our data, Patoc *ligB* displayed a reduced deposition of C3 compared to Patoc wt. However, there was no significant difference between Patoc *ligA* and Patoc wt (Fig. 4D). It is worth to mention that C3 deposition on serum resistant and serum sensitive *Leptospira* strains has been previously assessed [5,6]. Immunofluorescence microscopy assays revealed a similar pattern of C3 deposition on the surface of both pathogenic and non-pathogenic strains. Nevertheless, the late complement components C5, C6, C8 and MAC were detected only on the surface of the sensitive strain Patoc [6].

In the present work, no striking differences were observed regarding C4 fragments deposition (Fig. 4D), thus confirming previous data by our group demonstrating that *Leptospira* serum-sensitive, -intermediate, and -resistant strains bind similar amounts of C4 [5]. As expected, the levels of MAC deposition on the serum-sensitive strain Patoc wt and the serum-resistant strain Fromm differed substantially (Fig. 4D). MAC is the cytolytic end product of the complement cascade and its accumulation on the pathogenesis surface directly correlates with cell lysis. Interestingly, MAC deposition on both Patoc *ligA* and Patoc *ligB* was significantly reduced compared to Patoc wt, further confirming a crucial role of Lig proteins on aiding pathogenic *Leptospira* to avoid complement-mediated bacteriolysis.

Preliminary studies to assess the bacterial loads of *lig*-transformed *L. biflexa* strains in blood were performed and revealed that these strains presented similar half-life than wt *L. biflexa* in infected hamsters (data not shown). This data is in line with a previous study that shown that the infection with a *ligB* mutant of *L. interrogans* does not lead to loss of virulence and colonization in acutely and chronically infected animals, respectively [29]. Furthermore, it is worth to consider that the process of mutagenesis *per se* is sometimes unable to demonstrate the importance of a single virulence factor since other leptospiral proteins may provide functional redundancy [30,37]. By using *L. biflexa* as a surrogate host, we have shown that Lig proteins contribute to bacterial survival in human serum (Fig. 5), which is in line with recent results by Pappas and Picardeau [38] using Transcription Activator-Like Effectors (TALEs). These authors have shown that down regulation of both *ligA* and *ligB* in

pathogenic *L. interrogans* is required for virulence attenuation, thus attesting the importance of the Lig proteins for a successful infection [38].

## Acknowledgments

The authors do not have a commercial or other association that might pose a conflict of interest. This work was supported by the Grants2010/50043-0 and 2015/09972-0 from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).


## References

1. Pappas G, Papadimitriou P, Siozopoulou V, Christou L, Akritidis N. The globalization of leptospirosis: worldwide incidence trends. *Int J Infect Dis.* 2008; 12:351–357. [PubMed: 18055245]
2. Reis RB, Ribeiro GS, Felzemburgh RD, Santana FS, Mohr S, Melendez AX, Queiroz A, Santos AC, Ravines RR, Tassinari WS, Carvalho MS, Reis MG, Ko AI. Impact of environment and social gradient on *Leptospira* infection in urban slums. *PLoS Negl Trop Dis.* 2008; 2:e228. [PubMed: 18431445]
3. Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence: control and re-emerging leptospirosis: dynamics of infection in the changing world. *Clin Microbiol Infect.* 2011; 17:494–501. [PubMed: 21414083]
4. Fraga TR, Barbosa AS, Isaac L. Leptospirosis: aspects of innate immunity: immunopathogenesis and immune evasion from the complement system. *Scand J Immunol.* 2011; 73:408–419. [PubMed: 21204903]
5. Barbosa AS, Abreu PA, Vasconcellos SA, Morais ZM, Goncales AP, Silva AS, Daha MR, Isaac L. Immune evasion of leptospira species by acquisition of human complement regulator C4BP. *Infect Immunol.* 2009; 77:1137–1143. [PubMed: 19114549]
6. Meri T, Murgia R, Stefanel P, Meri S, Cinco M. Regulation of complement activation at the C3-level by serum resistant leptospires. *Microb Pathog.* 2005; 39:139–147. [PubMed: 16169184]
7. Fraga TR, dos Courrol DS, Castiblanco-Valencia MM, Hirata IY, Vasconcellos SA, Juliano L, Barbosa AS, Isaac L. Immune evasion by pathogenic *Leptospira* strains: the secretion of proteases that directly cleave complement proteins. *J Infect Dis.* 2014; 209:876–886. [PubMed: 24163418]
8. Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. *J Exp Med.* 1976; 144:1147–1163. [PubMed: 62817]
9. Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. *Proc Natl Acad Sci U S A.* 1976; 73:3268–3272. [PubMed: 1067618]
10. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. *J Exp Med.* 1977; 146:257–270. [PubMed: 301546]
11. Castiblanco-Valencia MM, Fraga TR, Silva LB, Monaris D, Abreu PA, Strobel S, Jozsi M, Isaac L, Barbosa AS. Leptospiral immunoglobulin-like proteins interact with human complement regulators factor H, FHL-1 FHR-1, and C4BP. *J Infect Dis.* 2012; 205:995–1004. [PubMed: 22291192]
12. Scharfstein J, Ferreira A, Gigli I, Nussenzweig V. Human C4-binding protein. I. isolation and characterization. *J Exp Med.* 1978; 148:207–222. [PubMed: 670886]
13. Gigli I, Fujita T, Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. *Proc Natl Acad Sci U S A.* 1979; 76:6596–6600. [PubMed: 293746]
14. Matsunaga J, Lo M, Bulach DM, Zuerner RL, Adler B, Haake DA. Response of *Leptospira interrogans* to physiologic osmolarity: relevance in signaling the environment-to-host transition. *Infect Immunol.* 2007; 75:2864–2874. [PubMed: 17371863]
15. Matsunaga J, Sanchez Y, Xu X, Haake DA. Osmolarity: a key environmental signal controlling expression of leptospiral proteins LigA and LigB and the extracellular release of LigA. *Infect Immunol.* 2005; 73:70–78. [PubMed: 15618142]




16. Choy HA, Kelley MM, Chen TL, Moller AK, Matsunaga J, Haake DA. Physiological osmotic induction of *Leptospira interrogans* adhesion: ligA and LigB bind extracellular matrix proteins and fibrinogen. *Infect Immunol.* 2007; 75:2441–2450. [PubMed: 17296754]
17. Lin YP, Chang YF. A domain of the *Leptospira* LigB contributes to high affinity binding of fibronectin. *Biochem Biophys Res Commun.* 2007; 362:443–448. [PubMed: 17707344]
18. Lin YP, Chang YF. The C-terminal variable domain of LigB from *Leptospira* mediates binding to fibronectin. *J Vet Sci.* 2008; 9:133–144. [PubMed: 18487934]
19. Lin YP, Greenwood A, Nicholson LK, Sharma Y, McDonough SP, Chang YF. Fibronectin binds to and induces conformational change in a disordered region of leptospiral immunoglobulin-like protein B. *J Biol Chem.* 2009; 284:23547–23557. [PubMed: 19581300]
20. Lin YP, Greenwood A, Yan W, Nicholson LK, Sharma Y, McDonough SP, Chang YF. A novel fibronectin type III module binding motif identified on C-terminus of *Leptospira* immunoglobulin-like protein. *LigB Biochem Biophys Res Commun.* 2009; 389:57–62. [PubMed: 19699715]
21. Lin YP, Lee DW, McDonough SP, Nicholson LK, Sharma Y, Chang YF. Repeated domains of leptospira immunoglobulin-like proteins interact with elastin and tropoelastin. *J Biol Chem.* 2009; 284:19380–19391. [PubMed: 19473986]
22. Lin YP, McDonough SP, Sharma Y, Chang YF. The terminal immunoglobulin-like repeats of LigA and LigB of *Leptospira* enhance their binding to gelatin binding domain of fibronectin and host cells. *PLoS One.* 2010; 5:e11301. [PubMed: 20585579]
23. Lin YP, Raman R, Sharma Y, Chang YF. Calcium binds to leptospiral immunoglobulin-like protein LigB, and modulates fibronectin binding. *J Biol Chem.* 2008; 283:25140–25149. [PubMed: 18625711]
24. Palaniappan RU, Chang YF, Jusuf SS, Artiushin S, Timoney JF, McDonough SP, Barr SC, Divers TJ, Simpson KW, McDonough PL, Mohammed HO. Cloning and molecular characterization of an immunogenic LigA protein of *Leptospira interrogans*. *Infect Immunol.* 2002; 70:5924–5930. [PubMed: 12379666]
25. Matsunaga J, Barocchi MA, Croda J, Young TA, Sanchez Y, Siqueira I, Bolin CA, Reis MG, Riley LW, Haake DA, Ko AI. Pathogenic *Leptospira* species express surface-exposed proteins belonging to the bacterial immunoglobulin superfamily. *Mol Microbiol.* 2003; 49:929–945. [PubMed: 12890019]
26. Croda J, Ramos JG, Matsunaga J, Queiroz A, Homma A, Riley LW, Haake DA, Reis MG, Ko AI. *Leptospira* immunoglobulin-like proteins as a serodiagnostic marker for acute leptospirosis. *J Clin Microbiol.* 2007; 45:1528–1534. [PubMed: 17360842]
27. Silva EF, Medeiros MA, McBride AJ, Matsunaga J, Esteves GS, Ramos JG, Santos CS, Croda J, Homma A, Dellagostin OA, Haake DA, Reis MG, Ko AI. The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. *Vaccine.* 2007; 25:6277–6286. [PubMed: 17629368]
28. Faisal SM, Yan W, Chen CS, Palaniappan RU, McDonough SP, Chang YF. Evaluation of protective immunity of *Leptospira* immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters. *Vaccine.* 2008; 26:277–287. [PubMed: 18055070]
29. Croda J, Figueira CP, Wunder EA Jr, Santos CS, Reis MG, Ko AI, Picardeau M. Targeted mutagenesis in pathogenic *Leptospira* species: disruption of the LigB gene does not affect virulence in animal models of leptospirosis. *Infect Immunol.* 2008; 76:5826–5833. [PubMed: 18809657]
30. Figueira CP, Croda J, Choy HA, Haake DA, Reis MG, Ko AI, Picardeau M. Heterologous expression of pathogen-specific genes ligA and ligB in the saprophyte *Leptospira biflexa* confers enhanced adhesion to cultured cells and fibronectin. *BMC Microbiol.* 2011; 11:129. [PubMed: 21658265]
31. Johnson RC, Muschel LH. Antileptospiral activity of normal serum. *J Bacteriol.* 1965; 89:1625–1626. [PubMed: 14291607]
32. Johnson RC, Harris VG. Antileptospiral activity of serum. II. Leptospiral virulence factor. *J Bacteriol.* 1967; 93:513–519.


33. Verma A, Hellwage J, Artiushin S, Zipfel PF, Kraiczy P, Timoney JF, Stevenson B. LfhA: a novel factor H-binding protein of *Leptospira interrogans*. *Infect Immunol.* 2006; 74:2659–2666. [PubMed: 16622202]
34. da Silva LB, dos Miragaia LS, Breda LC, Abe CM, Schmidt MC, Moro AM, Monaris D, Conde JN, Jozsi M, Isaac L, Abreu PA, Barbosa AS. Pathogenic *Leptospira* species acquire factor H and vitronectin via the surface protein LcpA. *Infect Immunol.* 2015; 83:888–897. [PubMed: 25534939]
35. Stevenson B, Choy HA, Pinne M, Rotondi ML, Miller MC, Demoll E, Kraiczy P, Cooley AE, Creamer TP, Suchard MA, Brissette CA, Verma A, Haake DA. *Leptospira interrogans* endostatin-like outer membrane proteins bind host fibronectin, laminin and regulators of complement. *PLoS One.* 2007; 2:e1188. [PubMed: 18000555]
36. Barbosa AS, Monaris D, Silva LB, Morais ZM, Vasconcellos SA, Cianciarullo AM, Isaac L, Abreu PA. Functional characterization of LcpA: a surface-exposed protein of *Leptospira spp.* that binds the human complement regulator C4BP. *Infect Immunol.* 2010; 78:3207–3216. [PubMed: 20404075]
37. McBride AJ, Cerqueira GM, Suchard MA, Moreira AN, Zuerner RL, Reis MG, Haake DA, Ko AI, Dellagostin OA. Genetic diversity of the Leptospiral immunoglobulin-like (Lig) genes in pathogenic *Leptospira spp.* *Infect Genet Evol.* 2009; 9:196–205. [PubMed: 19028604]
38. Pappas CJ, Picardeau M. Control of gene expression in leptospira spp by transcription activator-Like effectors demonstrates a potential role for LigA and LigB in *Leptospira interrogans* virulence. *Appl Environ Microbiol.* 2015; 81:7888–7892. [PubMed: 26341206]




**Fig. 1.** Acquisition of FH and C4BP by *lig*-transformed *L. biflexa*. Saprophyte *L. biflexa* serovar Patoc strain Patoc I (Patoc wt), pathogenic *L. interrogans* serovar Kennewicki strain Fromm (Fromm), and *L. biflexa* serovar Patoc strain Patoc I expressing LigA (Patoc *ligA*) or LigB (Patoc *ligB*) ( $2 \times 10^8$  bacteria) were incubated with 10% NHS as a source of FH (A) or C4BP (B), for 60 min at 37 °C. Leptospires were then washed five times with PBS, harvested and the whole cell lysates were subjected to Western blotting with anti-FH or anti-C4BP. Bands corresponding to FH (150 kDa), C4BP  $\alpha$  chain (70 kDa) and  $\beta$  chain (45 kDa) were detected. Densitometry analyses of bound FH (C) and C4BP (D) were performed using the program ImageJ. The density of the bands is expressed in Arbitrary Units (% relative) and was calculated considering *L. interrogans* Fromm as 100% of binding. (P) bacterial pellets; (W) aliquots of the last wash.

**Fig. 2.**

Heterologous expression of LigA and LigB in *L. biflexa* enhances bacterial survival in human serum. Saprophyte *L. biflexa* serovar Patoc strain Patoc I (Patoc wt), pathogenic *L. interrogans* serovar Kennewicki strain Fromm (Fromm), and *L. biflexa* serovar Patoc strain Patoc I expressing LigA (Patoc ligA) or LigB (Patoc ligB) ( $5 \times 10^8$  bacteria) were incubated with 20, 40 and 60% of normal human serum (NHS) for 60 and 120 min at 37 °C. Viable bacteria were counted by dark-field microscopy using a Petroff-Hausser chamber. The results are presented as relative survival to the survival of bacteria in heat-inactivated serum (100% growth). Means  $\pm$  the SD for three independent experiments, each performed in duplicate are shown. The data were analyzed with one way ANOVA test. \*( $p < 0.05$ ).


**Fig. 3.**

FH and C4BP bound to Patoc *ligA* and Patoc *ligB* retain cofactor activity. Patoc *ligA* and Patoc *ligB* ( $2 \times 10^8$  bacteria) were incubated with (A) purified FH, (B) purified C4BP or 5% NHS, as a source of these regulators. After washing, FI and C3b or C4b were added, and the reactions were incubated for 1, 2, and 4 h at 37 °C. The cleavage products of C3b and C4b were detected by Western blotting with specific antibodies. Control reactions in which FH or C4BP were omitted were also performed. (A) Fragments of 68, 46, 43, 38, 30 and 28 kDa indicate that the acquired FH was able to promote FI-mediated cleavage of C3b. (B) Fragments of 64 and 17 kDa indicate that bound C4BP was able to promote FI-mediated cleavage of C4b.



**Fig. 4.** Expression of LigA or LigB in *L. biflexa* controls deposition of MAC in the bacterial surface. Leptospire ( $2 \times 10^8$  bacteria) were incubated with 20% NHS for 60 min. After five washes, bacteria were incubated with polyclonal anti-human C3, anti-human C4 or anti-human MAC and then with the appropriate secondary antibodies for 30 min. Data are expressed as Mean Fluorescence Intensity (MFI)  $\pm$  SE of 3 independent experiments each performed in triplicate on a Fluorescent Activated Cell Sorter (FACS) Canto II (Benton Dickson). Data were analyzed using ANOVA-Tukey's Multiple Comparison Test ( $p < 0.005$ ).





**Fig. 5.** Schematic representation of complement inactivation on the surface of *L. biflexa* expressing LigA or LigB. Saprophytic *L. biflexa* are susceptible to complement-mediated killing because they do not bind the host regulators FH and C4BP. In contrast, *L. biflexa* expressing LigA or LigB evade complement attack by acquiring these soluble regulators. Alternative pathway evasion is mediated by FH binding to LigA/LigB and the consequent C3b cleavage by FI, using bound FH as a co-factor. Classical and lectin pathways inactivation is achieved by C4BP binding to LigA/LigB, followed by FI-mediated cleavage of C4b. In the schematic representation of FH and C4BP, each circle represents one SCR domain. Open circles indicate the three SCR domains of the C4BP  $\beta$ -chain.